EDUC-IC: Improving Knowledge in Heart Failure Inpatient With Therapeutic Education

Sponsor
University Hospital, Geneva (Other)
Overall Status
Recruiting
CT.gov ID
NCT05751772
Collaborator
Vifor Pharma (Industry), Labatec Pharma SA (Industry), Bayer (Industry), AstraZeneca (Industry)
124
1
2
14.6
8.5

Study Details

Study Description

Brief Summary

The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. The knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. The intervention group will receive a therapeutic education intervention and usual hospital care and the control group will receive only usual hospital care.

Detailed Description

Heart failure patients are at risk of decompensation of their disease and frequent hospitalizations. Poor adherence to their treatment may be the cause. By improving the knowledge of hospitalized heart failure patients about their disease and their medications, it is expected that these patients will adhere better to their heart failure drug therapy and benefit from a better effectiveness of their treatment. This could promote an improvement in their quality of life, a decrease in their risk of disease complications and even an increase in their life expectancy.

The objective of this research project is to deploy a therapeutic teaching intervention at the bedside of decompensated and hospitalized heart failure patients, associated with follow-up by the pharmacist at discharge from the hospital, and to measure its impact on knowledge change (primary endpoint), on their beliefs about medications, on their therapeutic adherence, and on the consumption of unplanned care such as rehospitalizations and emergency room visits (secondary endpoints).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single-center randomized controlled trialSingle-center randomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Disease and Medication Knowledge Improvement: A Swiss Single-center Randomized Controlled Trial With Heart Failure Inpatients
Actual Study Start Date :
Dec 13, 2022
Anticipated Primary Completion Date :
Dec 14, 2023
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

The intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)

Other: Patient therapeutic education
The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes: Targeted education on patient needs related to heart failure, heart failure medications and self-care; a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan; a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care).
Other Names:
  • inpatient therapeutic education interview and outpatient pharmaceutical follow-up
  • No Intervention: Control Group

    The control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.

    Outcome Measures

    Primary Outcome Measures

    1. Change in knowledge score [at the baseline time (zero time), immediately after therapeutic education intervention and 30 days after hospital discharge]

      Patients' level of knowledge about their disease and heart failure medications before the educational pharmaceutical intervention (pre-test) and immediately after the intervention (post-test n° 1) for the intervention group , as well as at 1 month after hospital discharge (post-test n°2) for the intervention and control group. It will be measured by means of a 17-question questionnaire specifically developed for this project. This level is valued by a minimum score of 0 points and a maximum of 17 points. Higher score means a better level of knowledge. The positive difference between pre-test and post-tes means an increase in knowledge and a negative difference means a decrease in knowledge.

    Secondary Outcome Measures

    1. Change in Beliefs about medicines Score [at the baseline time (zero time),30 days after hospital discharge]

      Beliefs about medicines will be measured via the specific Beliefs about Medicines Questionnaire (BMQs) score at baseline time (at the inclusion time)(pretest) and at 1 month after hospital discharge (post-test) in both groups. Scores range from 5 to 25 points for both subscales. The higher the score for the specific need, the more it means that the patient has a strong perception that he needs the drugs to be healthy and live. For specific concerns, the higher the score, the more the patient is concerned about a potential negative effect of taking the medication. A third score can be calculated by subtracting specific concerns from specific needs. This gives a score of -20 to +20. A positive value means that the need for the treatment exceeds the concerns of taking it.

    2. Change in Medication Adherence Score [at the baseline time (zero time),30 days after hospital discharge]

      Adherence will be assessed with the Three Item Self Report Scale at baseline time (at the inclusion time) (pre-test) and at 1 month after hospital discharge (post-test) in both groups. This questionnaire consists of 3 questions; one which evaluates the number of days of forgetting to take medication over the last month, one which evaluates the frequency of taking medication according to medical prescription and the third which makes it possible to measure the level of competence in the correct taking of medication that takes ownership of the patient. Responses are converted on a scale of 0 to 100 (0 is the lowest adherence and 100 the highest). An average of the three answers is used to assign the adhesion score.

    3. Level of satisfaction on therapeutic education [immediately after therapeutic education intervention]

      Patient satisfaction will be assessed using a 13-questions questionnaire specifically developed for this project, after the education interview to assess the usefulness and quality of the teaching intervention. There is no score related to the questionnaire. This qualitative assessment will allow us to determine whether this new intervention should be continued and to identify its strengths and weaknesses.

    4. Rehospitalization or emergency room visits [30 days after hospital discharge]

      The rate of rehospitalization or emergency room visits will be evaluated during the telephone call made by a research assistant at D30 post hospital discharge. The cause of hospitalization will be determined by means of the computerized hospital patient file if he is rehospitalized at the university hospital of Geneva (HUG) or directly to the patient (or his attending physician depending) if he is hospitalized in another hospital. It is interesting to assess whether the patient consumed unplanned care and whether it was related to instability of his heart failure.

    5. Death at 1 month after discharge [30 days after hospital discharge]

      The mortality rate will be assessed in both groups. This information can be collected from the participants' computerized patient records if mentioned or from the participants' relatives or attending physician.

    6. Patient experiment and feeling after discharge [7 days after hospital discharge]

      The patient's experience and feelings upon returning home will be assessed during a telephone call between D3 and D7 after the patient's discharge from the hospital. The objective will be to identify the patient's needs, their feelings about going home, what they liked, what they missed.

    7. CardioMeds app usability [30 days after hospital discharge]

      Use and usability of the mobile smartphone application (CardioMeds® ) will be explored by the research assistant during the telephone call at D30 post hospital discharge using a validated standardized questionnaire (System Usability Scale = SUS). SUS gives a single score representing a measure composite of the general user-friendliness of the studied service. The score ranges from 0 to 100.It is generally considered that a score is "good" from 75, fair or fair between 50 and 75. A score below 50 reveals major problems in terms of customer satisfaction.

    8. Self-Care of Heart Failure Index [30 days after hospital discharge]

      Self-care skills of patients using CardioMeds® will be explored using a validated score, the Self-Care of Heart Failure Index composed of 22 questions to measure the effect of this application on patients' level of empowerment in their care. The scale is subdivided in three measurement : maintenance score, management score and self-care confidence score. Each scale score is standardized to a 0 to 100 range. A score of ≥70 can be used as the cut-point to judge self-care adequacy,

    9. Level of satisfaction on global pharmaceutical care [30 days after hospital discharge]

      This second satisfaction questionnaire consisting of 8 questions specifically developed for this project, will be sent at 1 month after hospital discharge to assess the patient's overall satisfaction with the pharmaceutical care follow-up provided. There is no score related to the questionnaire. This qualitative assessment will allow us to determine whether the hospital pharmaceutical care

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Hospitalization in the Department of General Internal Medicine or Cardiology for decompensated heart failure with lowered left ventricular ejection fraction (LVEF) (≤40%) from any cause or mildly lowered LVEF (41-49%) with the presence of heart failure-specific drug therapy

    • Stability of the patient's clinical condition

    • ≥ 2 heart failure medications

    • ≥18 years

    • Full capacity of discernment

    • Absence of cognitive impairment

    • Ability to speak, understand and read in French

    • Get a personal telephone

    • Consent form signed by the participant

    Exclusion Criteria:
    • Inability to follow study procedures

    • Institutionalized persons

    • Asylum seekers, homeless people, prisoners

    • Incapacity of judgment and discernment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital of Geneva Geneva Switzerland 1205

    Sponsors and Collaborators

    • University Hospital, Geneva
    • Vifor Pharma
    • Labatec Pharma SA
    • Bayer
    • AstraZeneca

    Investigators

    • Study Director: Pascal Bonnabry, Professor, University of Geneva

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Mégane Jermini, Hospital and Clinical Pharmacist, pharmD, Principal Investigator, University Hospital, Geneva
    ClinicalTrials.gov Identifier:
    NCT05751772
    Other Study ID Numbers:
    • 2022-00731
    First Posted:
    Mar 2, 2023
    Last Update Posted:
    Mar 2, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mégane Jermini, Hospital and Clinical Pharmacist, pharmD, Principal Investigator, University Hospital, Geneva
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 2, 2023